The occurrence of cardiovascular complications associated with SARS-CoV-2 infection: a systematic

3 review

4 Daniele Melo Sardinha^{1*}, Karla Valéria Batista Lima^{2,3}, Thalyta Mariany Rêgo Lopes Ueno², Yan

5 Correa Rodrigues^{2,3}, Juliana Conceição Dias Garcez², Anderson Lineu Siqueira dos Santos^{2,3}, Ana

6 Lúcia da Silva Ferreira⁴, Ricardo José de Paula Souza e Guimarães^{1,3}, Luana Nepomuceno Gondim

- 7 Costa Lima^{1,2,3}
- 8 ¹ Programa de Pós-Graduação em Epidemiologia e Vigilância em Saúde (PPGEVS), Instituto Evandro Chagas
 9 (IEC), Ananindeua 67030-000, Brazil; danielle-vianna20@hotmail.com; ricardoguimaraes@iec.gov.br;
 10 luanalima@iec.gov.br.
- Programa de Pós-Graduação em Biologia Parasitária na Amazônica (PPGBPA), Instituto Evandro Chagas
 (IEC) e Universidade do Estado do Pará (UEPA), Belém 66087-670, Brazil; karlalima@iec.gov.br;
- 13 thalyta_mlopes@hotmail.com; Yan.13@hotmail.com; juliana.garcez@famaz.edu.br;
- 14 andersonlineu@gmail.com.
- 15 ³ Seção de Bacteriologia e Micologia (SABMI), Instituto Evandro Chagas (IEC), Ananindeua 67030-000, Brazil.
- 16 ⁴ Secretaria de Estado de Saúde Pública do Pará (SESPA), Belém, 66017-000, Brazil;
 17 analucia.ferreira@sespa.pa.gov.br.

18 ⁵ Laboratório de Geoprocessamento, Instituto Evandro Chagas (IEC), Ananindeua 67030-000, Brazil;

19 * Correspondence: danielle-vianna20@hotmail.com; Tel.: +55 91998188790 (DMS)

20 Abstract: The Cardiovascular Diseases represent the main cause of death in the world, and are 21 associated as risk factors that cause serious complications in cases of infections, such as those of the 22 respiratory tract. In March 2020 the World Health Organization declared a pandemic for 23 SARS-CoV-2, a new coronavirus causing severe pneumonia, which emerged in December 2019 in 24 Wuhan, China. The objective is to investigate the occurrence of cardiovascular complications 25 associated with SARS-CoV-2 infection. It is a systematic review, quantitative, in the databases, 26 PubMed and Science direct, including primary studies with hospitalized patients confirmed for 27 COVID-19 and who presented cardiovascular complications, form used tools for evaluation of 28 quality and evidence, following the PRISMA recommendations. Results: 12 studies were included. 29 The occurrence of cardiovascular complications was: 27.35% of the sample of 3,316 patients. Types: 30 Acute cardiac injury 17.09%; Thromboembolism 4.73%; Heart failure 3.43%; Arrhythmias 1.77%; 31 Brain stroke 0.33%. Mean age 61 years. Conclusions: This study showed that there are several 32 cardiovascular complications associated with SARS-CoV-2, that the main one is the acute cardiac 33 injury, which causes several instabilities in the cardiopulmonary system, and that it is associated 34 with mortality.

- 35 Keywords: Cardiovascular Complications; COVID-19; SARS-CoV-2.
- 36

37 1. Introduction

The Cardiovascular Diseases (CD) are a set of pathological conditions involving the cardiovascular system, such as: Coronary Arterial Disease (CAD), Cardiac Arrhythmias, Valvopathy, Inflammatory Heart Disease, Heart Failure (HF), Vascular Brain Injury (VBI), Pulmonary Embolism (PE), and Deep Venous Thrombosis (DVT). However, some risk factors, modifiable and non-modifiable, potentiate or cause cardiovascular events, among them: Systemic Arterial Hypertension (SAH), Diabetes Melittus (DM), Dyslipidemias, Sedentarism, Obesity, Stress, Hormone replacement therapy, Smoking, Family history of CD, Sex, Age and Heredity[1,2].

Thus, CD represents a major public health problem, since it is the leading cause of death, accounting for 17.7 million deaths worldwide in 2015, representing 31% of all deaths globally. The main cause of deaths is CAD [3,4].

It is made available under a CC-BY-NC-ND 4.0 International license .

48 In this context, previous research has shown a transient risk of acute vascular events, including 49 myocardial infarction and cardiovascular deaths, after clinically diagnosed Acute Respiratory 50 Infections (ARI). Influenza vaccine has been shown to minimize the risk of major adverse cardiac 51 events among people with pre-existing cardiovascular disease. Studies have shown that influenza 52 epidemics are associated with cardiovascular mortality in subtropical and tropical climates. Thus, 53 seasonal mortality from all causes, specifically in the elderly, has been associated with several 54 viruses, including influenza, parainfluenza, RSV and norovirus. A Dutch study suggests that these 55 viruses account for 6.8% of deaths in people aged \geq 85, 4.4% in people aged 75-84, and 1.4% in people 56 aged 65-74. The impact of viral respiratory infections on the cardiovascular system causing fatal 57 events is thus evident[5,6].

In this sense, in December 2019, cases of influenza syndrome with evolution to ARI, of unknown etiology, were registered in China and caused concern because of the several deaths and rapid transmissibility. In January researchers isolated and identified the causative infectious agent as a Coronavirus, named at the time 2019-nCov, however, due to the similarity to SARS-CoV, another coronavirus causing ARI in humans, was renamed by the World Health Organization (WHO) as SARS-CoV-2, and respectively the disease was named Cov Disease-19 (COVID-19)[7–9].

Soon, COVID-19, due to the high transmissibility via respiratory droplets, in a direct and
indirect way, spread to neighboring countries, and reached the level of the pandemic in March 2020
declared by the WHO[10].

67 According to the studies, the clinical characteristics of COVID-19 have shown to evolve in three 68 ways: Flu Syndrome (FS), Severe Acute Respiratory Syndrome (SARS) and Asymptomatic. In the FS 69 it refers to the presentation of fever, cough, sore throat, coryza, nasal congestion and myalgia. In 70 SARS, signs and symptoms of FS are associated with oxygen saturation equal to or <95%, beating of 71 nose wings, diarrhea, nausea, vomiting and cyanosis. The cases of SARS represent the serious 72 complications of COVID-19, requiring intensive care treatment and being responsible for several 73 deaths. The following risk factors stand out for the evolution of SARS: chronic heart diseases, 74 chronic respiratory diseases, neoplasms, elderly, pregnant women, obese people[11–13].

In a review study, several cardiovascular complications associated with SARS-CoV-2 infection were cited[14]. However, studies do not specify the most frequent and prevalent associated complications, so it was questioned: What is the occurrence of cardiovascular complications associated with SARS-CoV-2 infection? The objective of this research is to investigate the occurrence of cardiovascular complications associated with SARS-CoV-2 infection.

80 2. Materials and Methods

Exploratory-descriptive research, of the type Systematic Review (SR), following the PRISMA
recommendations [15]. The SR is made up of five stages: 1. formulating a research question; 2.
defining inclusion and exclusion criteria; 3. developing a research strategy and researching the
literature - finding the studies; 4. selecting the studies; 5. evaluating the quality of the studies; 6.
extracting the data; 7. summarizing the data and evaluating the quality of the evidence;[16].

For the elaboration of the research question, we used the PICO strategy, widely used in
evidence-based practice, in which it proposes that problems identified in clinical practice, research
and teaching be organized from four elements: Patient; Intervention; Comparison; Outcome (PICO).
Because the construction from these elements, provides greater scope for the resolution of the
problem addressed [17].

Research question: What is the occurrence of cardiovascular complications associated with
 SARS-CoV-2 infection cited in the literature? Patient: Infected with SARS-CoV-2 of any age group,
 hospitalized / Intervention: identify the cardiovascular complications associated with SARS-CoV-2 /
 Comparison: Not applicable / Outcome: Describe the occurrence of cardiovascular complications
 associated with SARS-CoV-2 cited in the literature.

For the search strategy in the literature, the following keywords were listed: cardiovascular
complications; COVID-19; SARS-CoV-2. The selected databases were: PubMed, Science direct,
including studies of any language, published from 2019 until the date of the search 11/07/2020.

It is made available under a CC-BY-NC-ND 4.0 International license .

Inclusion criteria: primary studies, which evaluated individuals infected by SARS-CoV-2
 hospitalized and presented results on cardiovascular complications, of all age groups. Exclusion
 criteria: studies that do not specify the cardiovascular complications that occurred quantitively.

102 The PRISMA flowchart, a tool that is part of the PRISMA protocol, was used to visualize the 103 search in the databases, showing how the final sample was reached, describing all the stages and 104 inclusion and exclusion [15].

105According to the protocol, two reviewers researched the bases independently, and critically106evaluated each study from exhaustive reading in two stages, sorting by titles and abstracts/complete107text. They then met twice to discuss the evaluations and decided which studies were included in the108research.

109 The U.S. National Institutes of Health's Quality Assessment Tool for Observational Cohort and 110 Cross-Sectional Studies was used to assess the quality of studies 111 (https://www.nhlbi.nih.gov/health-topics/ study-quality-assessment-tools) It consists of 14 questions 112 that measure the representativeness, the type of sampling, the description and evaluation of the 113 exposure, the participants' overbite and the adjustments and qualifications of the confounding 114 variables. The results were discussed qualitatively among the researchers, and the disparities were 115 solved through the discussion.

In the evaluation of the quality of evidence, the Oxford Centre for Evidence-Based Medicine's
 Quality Classification Scheme was used for studies and other evidence [18], which is based on levels
 1 to 5:

119 1- Randomized clinical trial properly fed and conducted; systematic review with meta-analysis.

120 2- Well designed controlled trial without randomization; comparative prospective cohort study.

121 3- Case control studies; retrospective cohort study.

122 4- Series of cases with or without intervention; transversal study.

123 5- Opinion of respected authorities; case reports.

When extracting the data, the researchers developed a form consisting of the following variables: authors and year of publication, method, quality of evidence, location, age, participants, gender, comorbidities, estimates of occurrence of cardiovascular complications evidenced in those infected by SARS-CoV-2. For data analysis, we opted for descriptive statistics, chi-square test of independence applied in the participants with the complications, to observe the most significant complications. The results were presented in tables.

130 3. Results


In PubMed, the initial search resulted in 294 articles, after the analysis by title and objective, 46 were selected for reading. 7 articles were included for the data analysis [19], [20], [21], [22], [23], [24], [25]. In Science direct, 795 articles were initially searched, applying the filter for primary articles only resulted in 257. 45 were selected, and after reading 5, [26], [27], [28], [29], [30]. In figure 1 is the flowchart of the search, and in table 1 the detailing of the variables extracted from the studies.

- 136
- 137

Figure 1 - Characterization of the search and definition of the sample in the databases.

138

It is made available under a CC-BY-NC-ND 4.0 International license .



139

141

140 Source: Authors.

 Table 1.
 Data extracted from the studies included in the review.

First author and year	Metodo	Quality of evidence	Location/ sample	Age	Sex	Comorbidities	The occurrence and cardiovascular complications
Li et al	Retrospective		China	Average 60	Male 279 (50,9%)	Chronic obstructive pulmonary disease 17 (3.1%)	Cardiac injury119 (21.7%).
(2020).	study with	3	548	years	Female 269 (49,1%)	Asthma5 (0.9%)	Diffuse intravascular coagulation
	patients			(range 48		Tuberculosis (1.6%)	42 (7.7%).
	Hospitalized			69)		Diabetes 83 (15.1%)	
						Hypertension 166 (30.3%)	
						Coronary heart disease 34 (6.2%)	
						Hepatitis B 5 (0.9%)	
						Chronic kidney disease 10 (1.8%)	
						Tumor24 (4.7%)	
Wang et al	Retrospective		China	Average 71	Male 166 (49%)	Heart Disease 53 (15.7%)	Acute cardiac injury 70 (21.0%)
(2020).	cohortin	3	339	years (> 60)	Female 173 (51%)	Hypertension 138 (40.8%)	Arrhythmia 35 (10.4%)
	onehospital, all					Diabetes 54 (16%)	Heart failure 58 (17.4%)
	confirmed cases					Kidney Disease 13 (3.8%)	
	of COVID-19					Chronic Liver Disease 2 (0.6%)	
	over 60 years of					Pneumopathy 21 (6.2%)	
	age					Autoimmune disease 5 (1.5%).	
Inciardi et al	Retrospective		Italy	Average 67	Male 80 (81%)	Hypertension 63 (64%)	Venous thromboembolism 12 (12%)
(2020).	cohort with	3	99		Female 19 (19%)	Dyslipidemia29 (30%)	
	hospitalized					Diabetes30 (31%)	Arterial thromboembolism 3 (3%)
	patients					Heart failure 21 (21%)	
						Atrial fibrillation 19 (19%)	
						Coronary artery disease 16 (16%)	

						Chronic obstructive pulmonary disease 9 (9%) Chronic kidney disease 15 (15%) Cancer 17 (18%)	
Shi et al (2020a).	Retrospective study with hospitalized patients	3	China 671	Median 63 (50–72)	Male 322 (48%) Female 349 (52%)	Hypertension199 (29.7%) Diabetes97 (14.5%) Coronary heart disease 60 (8.9%) Chronic kidney disease28 (4.2%) Chronic obstructive pulmonary disease 23 (3.4%) Cancer23 (3.4%) Heart Failure 22 (3.3%) Cerebrovascular disease 22 (3.3%) Atrial fibrillation 7 (1.0%)	Myocardial injury 106 (15.8%) Heart Failure 12
Li et al (2020).	Retrospective observational study of hospitalized patients	3	China 219	Median 53	Male 89 (39.7%) Female 130 (60,3%)	Hypertension 55 (25.1%) Diabetes 31 (14.2%) Heart disease 17 (7,8%)	Stroke 11 (5%)
Shi et al (2020Ь).	Cohort with hospitalized	3	China 416	Median 64 (21-95)	Male 205 (49,3%) Female 211 (50,7%)	Hypertension 127 (30.5%) Diabetes 60 (14.4%) Coronary heart disease 44 (10.6%) Cerebrovascular disease 22 (5.3%) Heart Failure 17 (4.1%) Chronic renal failure 14 (3.4%)	Cardiac Injury 82 (19,7%).

						Chronic obstructive pulmonary disease 12 (2.9%) Cancer 9 (2.2%)	
Guo et al	Series of		China	Average 58	Male 91 (48.7%)	Hypertension61 (32.6%)	Myocardial injury 52 (27.8%)
(2020).	hospitalized	3	187	(14-66)	Female 96 (51,3%)	Coronary Heart Disease 21 (11.2%)	Coagulopathy 42 (34,1%)
	cases					Cardiomyopathy 8 (4.3%)	
						Diabetes 28 (15.0%)	
						Chronic obstructive pulmonary disease 4 (2.1%)	
						Malignancy 13 (7.0%)	
						Chronic kidney disease6 (3.2%)	
Yang et al	Observational		China	Average 55	Male 98 (49%)	Hypertension 45 (22.5%)	Acute cardiac injury 20 (10%)
(2020).	study of	3	200		Female 102 (51%)	Chronic lung disease 7 (3.5%)	
	hospitalized					Diabetes 21 (10.5%)	
	patients					Chronic heart disease 11 (5.5%)	
						Chronic kidney disease3 (1.5%)	
						Chronic liver disease 2 (1%)	
Zhou et al	Retrospective		China	Average 56	Male 119 (62%)	Hypertension 58 (30%)	Heart failure44 (23%)
(2020).	and multicenter	3	191	(18-87)	Female 72 (38%)	Diabetes 36 (19%)	Coagulopathy37 (19%)
	cohort study,					Coronary heart disease 15 (8%)	Acute cardiac injury 33 (17%)
	with hospitalized					Chronic obstructive pulmonary disease 6 (3%)	
						Carcinoma 2 (1%)	
Zhang et al	Retrospective		China	Average 55	Male 108 (48.9%)	Hypertension 54 (24.4%)	Arrhythmia24 (10.9%)
(2020).	study with	3	221	(39-66)	Female 113 (51,1%)	Diabetes 22 (10.0%)	Acute cardiac injury 17 (7,7%)
	hospitalized					Cardiovascular disease 22 (10.0%)	
						Cerebrovascular disease 15 (6.8%)	

						Chronic obstructive pulmonary disease 6 (2.7%)	
						Chronic kidney disease6 (2.7%)	
						Chronic liver disease7 (3.2%)	
						Immunosuppression 3 (1.4%)	
Shang et al	Retrospective		China	Median 66	Male 73 (64%)	Hypertension 50 (44%)	Acute myocardial injury 44 (38.9%
(2020).	cohort study with	3	113		Female 40 (36%)	Diabetes 20 (17.7%)	Coagulopathy 21 (18,6%)
	severe					Coronary heart disease 28 (24.8%)	
	hospitalized					Chronic obstructive pulmonary disease 5 (4%)	
						Tumor8 (7.1%)	
						Heart disease 9 (8.0%)	
						Liver disease 8 (7.1%)	
Deng et al	Retrospective		China	Average 65	Male 57 (50.9%)	Chronic obstructive pulmonary disease 4 (3.6%)	Myocardial injury 14 (12,5%)
(2020).	with hospitalized	3	112	(49-60)	Female 55 (49,1%)	Hypertension 36 (32.1%)	
						Diabetes 19 (17.0%)	
						Coronary artery disease 15 (13.4%)	
						Atrial fibrillation 4 (3.6%)	

142

Source: Authors.

It is made available under a CC-BY-NC-ND 4.0 International license .

Based on the analysis of the included studies and the extracted variables, the review gathered 3. 316 participants of the studies who were hospitalized, 50.87% male and 49.12% female, mean age 61 years, 13.08% with heart diseases (heart failure and coronary disease were included in heart diseases), 15.10% diabetes, 31.72% hypertension, 3.5% pneumopathy (obstructive pulmonary disease was included in pneumopathy), 3.13% renal diseases, 2.89% cancer, 0. 09% immunosuppression, 0.57% liver disease, 0.15% autoimmune disease and 0.27% tuberculosis. This shows the most frequent comorbidities are: Hypertension, Diabetes and Cardiac Diseases (table 2).

	Yes		No	Tota	1
n	%	n	%	n	%
1629	49,12545	1687	50,87455	3316	100
1687	50,87455	1629	49,12545	3316	100
				3316	100
434	13,08806	2882	86,91194	3316	100
501	15,10856	2815	84,89144	3316	100
1052	31,72497	2264	68,27503	3316	100
119	3,588661	3197	96,41134	3316	100
104	3,136309	3212	96,86369	3316	100
96	2,895054	3220	97,10495	3316	100
3	0,09047	3313	99,90953	3316	100
19	0,572979	3297	99,42702	3316	100
5	0,150784	3311	99,84922	3316	100
9	0,271411	3307	99,72859	3316	100
	1629 1687 434 501 1052 119 104 96 3 19 5	n % 1629 49,12545 1687 50,87455 434 13,08806 501 15,10856 1052 31,72497 119 3,588661 104 3,136309 96 2,895054 3 0,09047 19 0,572979 5 0,150784	n % n 1629 49,12545 1687 1687 50,87455 1629 434 13,08806 2882 501 15,10856 2815 1052 31,72497 2264 119 3,588661 3197 104 3,136309 3212 96 2,895054 3220 3 0,09047 3313 19 0,572979 3297 5 0,150784 3311	n % n % 1629 49,12545 1687 50,87455 1687 50,87455 1629 49,12545 434 13,08806 2882 86,91194 501 15,10856 2815 84,89144 1052 31,72497 2264 68,27503 119 3,588661 3197 96,41134 104 3,136309 3212 96,86369 96 2,895054 3220 97,10495 3 0,09047 3313 99,90953 19 0,572979 3297 99,42702 5 0,150784 3311 99,84922	n $\%$ n $\%$ n162949,12545168750,874553316168750,87455162949,125453316168750,87455162949,12545331643413,08806288286,91194331650115,10856281584,891443316105231,72497226468,2750333161193,588661319796,4113433161043,136309321296,863693316962,895054322097,10495331630,09047331399,909533316190,572979329799,42702331650,150784331199,849223316

150 Table 2 - Characteristics of participants, gender, mean age and comorbidities.

151 Source: Authors.

Regarding the occurrence of cardiovascular complications associated with the SARS-CoV-2
infection, the following were highlighted: acute cardiac injury 17.09%, thromboembolism 4.73%,
heart failure 3.43%, arrhythmias 1.77%, and stroke 0.33% (Table 3).

155 Table 3 - Occurrence of cardiovascular complications associated with SARS-CoV-2.

	Yes		No		Total		P-value
	n	%	n	%	n	%	
General complications	908	27,35%	2408	72,65%	3316	100	< 0.0001
Types							
Cardiac injury	567	17,09891	2749	82,90109	3316	100	
Thromboembolism	157	4,73462	3159	95,26538	3316	100	
Heart failure	114	3,437877	3202	96,56212	3316	100	<0.0001*
Arrhythmias	59	1,779252	3257	98,22075	3316	100	
Stroke	11	0,331725	3305	99,66828	3316	100	

It is made available under a CC-BY-NC-ND 4.0 International license .

156 Source: Authors. * Chi-square: independence test.

157 4. Discussion

Infection with SARS-CoV-2 may manifest with mild symptoms (85%) and severe symptoms
(15)% (such as progression to SARS) with the potential to cause extrapulmonary damage, including
cardiovascular damage that directly influences morbidity and mortality [31].

161 Thus, this study showed, from the analysis of studies with 3,316 hospitalized patients 162 confirmed for COVID-19, that the occurrence of cardiovascular complications associated with 163 SARS-CoV-2 was 27.35% of the following types: Acute cardiac injury 17.09%; Thromboembolism 164 4.73%; Heart failure 3.43%; Arrhythmias 1.77%; Brain stroke 0,33%.

165 Acute cardiac injury was the most recurrent, and two meta-analysis studies showed its juto 166 association with increased troponin and mortality, showing no association of the cardiac injury with 167 higher risk of developing SARS. The studies highlight that early troponin monitoring is a preventive 168 strategy for further myocardial injury[32,33]. This mechanism of injury is not yet clear to 169 cardiologists, however, they work with hypotheses of viral invasion in the myocardium, similar to 170 pulmonary invasion, via the connection of SARS-CoV-2 to the Angiotensin Converting Enzyme 2 171 (ACE2), which is extensively present in the myocardium. Additionally, pneumonia can influence 172 through systemic inflammatory responses, causing non-ischemic complications in the myocardium, 173 mainly in the presence of cardiovascular comorbidities. It is also noted that the increased 174 inflammatory activity is a risk factor for the rupture of coronary atherosclerotic plaques, which can 175 cause the partial or total blockage of coronary arteries, causing myocardial ischemia and 176 consequently hypoxia injury, characterizing Acute Myocardial Infarction. Causes of 177 cardiomyopathy due to stress, physical injury, or pharmacological effects were not excluded.[34,35].

178 Research characterizes that the occurrence of acute cardiac injury is highly related to the 179 presence of cardiovascular comorbidities (such as hypertension and diabetes), admission to an 180 Intensive Care Unit and mortality. They highlight as a characteristic the increase of troponin type I 181 associated with electrocardiographic and echocardiographic alterations, presenting segmental 182 abnormality of the wall movement or reduction of the left ventricle ejection fraction [36]. Thus, the 183 clinical presentation of the acute cardiac lesion may manifest as myocarditis or acute myocardial 184 infarction, with thoracic pain and ST-segment elevation, requiring percutaneous cardiac 185 procedure[37,38], which is an intervention that presents a risk of acute renal failure in hospitalized 186 patients with comorbidities, due to the use of contrasts, and can increase hospitalization and 187 mortality [39]. Showing that this complication requires procedures that can influence or enhance 188 clinical conditions for a worse outcome.

189 Thromboembolism was the second most recurrent cardiovascular complication, described in 190 the literature as Disseminated Intravascular Coagulation. In association with SARS-CoV-2, it is 191 related to a storm of inflammatory cytokines, directly attacking the vascular endothelium with 192 elevation of the fibrinogen and dimero-D markers (product of fibrin/fibrinogen degradation), 193 causing thrombin dysregulation, exacerbated by inhibition of fibrinolysis. Thus the natural 194 anticoagulants are compromised, resulting in the formation of thrombi, which can travel to a smaller 195 vessel and obstruct, causing hypoxia. Thromboses can be venous or arterial, and can evolve to Deep 196 Venous Thrombosis, Pulmonary Embolism, Ischemic Vascular Accident or acute myocardial 197 infarction. These are serious complications associated with mortality. In this context, the heparin 198 used in anticoagulant therapy was associated with better prognosis in some cases[40,41]. A study 199 with 184 patients hospitalized in an intensive care unit confirmed for COVID-19, showed an 200 incidence of 31% of thrombotic events, all received standard dose tombroprophylaxis[42]. Another 201 study with 388 patients hospitalized by COVID-19 with thrombotic events in 28 cases (7.7%), being 8 202 cases in intensive care unit and 20 cases in the infirmary, the complications represented: 4.4% venous 203 thromboembolism, 2.8% Pulmonary Embolism, 0.3% Deep Venous Thrombosis, 2.5% ischemic 204 stroke and 11.1% acute myocardial infarction and Acute Coronary Syndrome. All cases used 205 tombroprophylaxis[43]. This study also showed the occurrence of stroke alone as a complication in

It is made available under a CC-BY-NC-ND 4.0 International license .

0.33% of cases, however, it is directly associated with thromboembolism associated with
 SARS-CoV-2, because the inflammatory response generates a hypercoagulable condition.

208 Heart failure represented the third cardiovascular complication, being a complex clinical 209 syndrome, in which the myocardium has inability to adequately pump the blood to meet the 210 metabolic needs of the tissues. This condition can be caused by structural or functional cardiac 211 changes and presents characteristic signs and symptoms that result from a reduction in cardiac 212 output and/or high filling pressures at rest or under stress[44]. Studies show that this complication 213 occurs in patients without heart disease, mainly as a consequence of acute heart injury, since the 214 damage to the myocardium has repercussions on its ventricular contraction function, resulting in a 215 reduction in systolic function. Additionally, coagulopathies can cause pulmonary embolism and 216 have repercussions in acute right ventricular failure. In addition, stress cardiomyopathy can also 217 lead to classic ventricular decompensation, with high filling pressures and pulmonary edema. On 218 the other hand, in the carrier of chronic heart failure, there is a great chance of decompensation of the 219 disease, requiring hospitalization and intensive care, influencing mortality[45,46].

Another outstanding complication was cardiac arrhythmias, which are directly related to the following factors: acute cardiac injury, heart failure, drugs that prolong the cQT interval. Atrial fibrillation proved to be the most common type of arrhythmia, with the potential risk of thrombus formation, acute myocardial infarction and ischemic stroke, and antithrombotic therapy is debatable even in cases without risk factors. Arrhythmias are also related to higher risks of heart instability, cardiac arrest and death[47].

This review showed that acute cardiac injury is the main cardiovascular complication associated with SARS-CoV-2 infection, causing several instabilities in cardiopulmonary functions, and also influencing other cardiovascular complications, in patients without chronic diseases and with chronic diseases.

230 5. Conclusions

The main cardiovascular complications associated with SARS-CoV-2 in hospitalized patients were several, among them: acute cardiac injury, thromboembolism, heart failure, arrhythmias and ischemic stroke, with a mean age of 61 years, with the most prevalent comorbidities, hypertension, diabetes and heart diseases.

The evidence on the association of cardiovascular complications and SARS-CoV-2 provides information for the implementation of preventive measures and better therapeutic management, with the objective of minimizing hospital stay, morbidity and mortality.

Author Contributions: D.M.S and K.V.B.L. conceived the study. D.M.S, K.V.B.L. and T.M.R.L.U. designed the search strategy. D.M.S. conducted searching of databases. Y.C.R., D.M.S., J.C.D.G. and A.L da S.F. screened the records. D.M.S and K.V.B.L. screened the full texts. A.L.S dos. S. completed all data extraction, and R.J. de P.S e G and L.N.G.C.L. conducted quality checks. L.N.G.C.L. drafted the full manuscript, and all authors reviewed and approved final submission. All authors have read and agreed to the published version of the manuscript

Funding: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ). Coordenação de
 Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Instituto Evandro Chagas (IEC).

245 Conflicts of Interest: The authors declare no conflict of interest.

246 References

- 247 [1] Sardinha DM, Silva AGI da, Gomes SG, Pamplona FC, Gorayeb ALDS, Ferreira MFDC, et al.
 248 Cardiovascular Risk Factors in Nurses Teachers. Cardiol Angiol An Int J 2020;9:9–17.
 249 https://doi.org/10.9734/ca/2020/v9i130125.
- [2] Costa GF, Sardinha DM, Oliveira VMLP, Barata FS, Silva PHV da, Mafra INP, et al. Nursing Care for
 Patients Submitted to Coronary Transluminal Angioplasty: An Integrative Review. Cardiol Angiol An Int
 [252] J 2020;9:18–26. https://doi.org/10.9734/ca/2020/v9i130126.
- 253 [3] Massa KHC, Duarte YAO, Chiavegatto Filho ADP. Análise da prevalência de doenças cardiovasculares e

254		fatores associados em idosos, 2000-2010. Cien Saude Colet 2019;24:105–14.
255		https://doi.org/10.1590/1413-81232018241.02072017.
256	[4]	OMS OM da S. OPAS/OMS Brasil - Doenças cardiovasculares. PahoOrg 2017.
257		$https://www.paho.org/bra/index.php?option=com_content \&view=article \&id=5253: doen cas-cardiovascula and the second sec$
258		res&Itemid=1096 (accessed July 11, 2020).
259	[5]	Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed Respiratory
260		Infections as Predictors of Hospital Admission for Myocardial Infarction and Stroke: Time-Series Analysis
261		of English Data for 2004-2015. Clin Infect Dis 2018;67:8–17. https://doi.org/10.1093/cid/cix1144.
262	[6]	Davidson JA, Warren-Gash C. Cardiovascular complications of acute respiratory infections: current
263		research and future directions. Expert Rev Anti Infect Ther 2019;17:939-42.
264		https://doi.org/10.1080/14787210.2019.1689817.
265	[7]	Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Heal 2020;25:278–80.
266		https://doi.org/10.1111/tmi.13383.
267	[8]	Lima LNGC, De Sousa MS, Lima KVB. As descobertas genômicas do SARS-CoV-2 e suas implicações na
268		pandemia de COVID-19. J Heal Biol Sci 2020;8:1.
269		- https://doi.org/10.12662/2317-3076jhbs.v8i1.3232.p1-9.2020.
270	[9]	BULUT C, KATO Y. Epidemiology of COVID-19. TURKISH J Med Sci 2020;50:563–70.
271		https://doi.org/10.3906/sag-2004-172.
272	[10]	Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol
273		2020;92:548–51. https://doi.org/10.1002/jmv.25722.
274	[11]	Brasil M da S. Definição de Caso e Notificação. Portal Do Gov Bras 2020:1–9.
275		https://coronavirus.saude.gov.br/definicao-de-caso-e-notificacao (accessed July 4, 2020).
276	[12]	Bastos LS, Niquini RP, Lana RM, Villela DAM, Cruz OG, Coelho FC, et al. COVID-19 e hospitalizações por
277		SRAG no Brasil: uma comparação até a 12ª semana epidemiológica de 2020. Cad Saude Publica 2020;36.
278		https://doi.org/10.1590/0102-311x00070120.
279	[13]	Madabhavi I, Sarkar M, Kadakol N. COVID-19. A review. Monaldi Arch Chest Dis 2020;90.
280		https://doi.org/10.4081/monaldi.2020.1298.
281	[14]	Martins JDN, Sardinha DM, Silva RR da, Lima KVB, Lima LNGC. As implicações da COVID-19 no sistema
282		cardiovascular: prognóstico e intercorrências. J Heal Biol Sci 2020;8:1.
283		https://doi.org/10.12662/2317-3076jhbs.v8i1.3355.p1-9.2020.
284	[15]	Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA Statement
285		for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions:
286		Explanation and Elaboration. PLoS Med 2009;6:e1000100. https://doi.org/10.1371/journal.pmed.1000100.
287	[16]	Donato H, Donato M. Stages for undertaking a systematic review. Acta Med Port 2019;32:227-35.
288		https://doi.org/10.20344/amp.11923.
289	[17]	Santos CMDC, Pimenta CADM, Nobre MRC. A estratégia PICO para a construção da pergunta de
290		pesquisa e busca de evidências. Rev Latino-Am Enferm 2007;15:508–11.
291		https://doi.org/10.1590/S0104-11692007000300023.
292	[18]	Oxford Centre for Evidence-Based Medicine. Evaluation of the quality of evidence. CEBEM 2020.
293		https://www.cebm.net/ (accessed September 18, 2020).
294	[19]	Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19
295		inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110–8. https://doi.org/10.1016/j.jaci.2020.04.006.
296	[20]	Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients:

It is made available under a CC-BY-NC-ND 4.0 International license .

297 Characteristics and prognostic factors based on 4-week follow-up. J Infect 2020;80:639-45. 298 https://doi.org/10.1016/j.jinf.2020.03.019. 299 [21] Inciardi RM, Adamo M, Lupi L, Cani DS, Di Pasquale M, Tomasoni D, et al. Characteristics and outcomes 300 of patients hospitalized for COVID-19 and cardiac disease in Northern Italy. Eur Heart J 2020;41:1821-9. 301 https://doi.org/10.1093/eurheartj/ehaa388. 302 [22] Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, et al. Characteristics and clinical significance of myocardial 303 injury in patients with severe coronavirus disease 2019. Eur Heart J 2020;41:2070-9. 304 https://doi.org/10.1093/eurheartj/ehaa408. 305 [23] Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, et al. Acute cerebrovascular disease following COVID-19: a 306 2020. single center, retrospective, observational study. Stroke Vasc Neurol 307 https://doi.org/10.1136/svn-2020-000431. 308 [24] Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in 309 Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802. 310 https://doi.org/10.1001/jamacardio.2020.0950. 311 [25] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of 312 Patients With Coronavirus Disease 2019 (COVID-19). Cardiol 2020. JAMA 313 https://doi.org/10.1001/jamacardio.2020.1017. 314 [26] Yang L, Liu J, Zhang R, Li M, Li Z, Zhou X, et al. Epidemiological and clinical features of 200 hospitalized 315 patients with corona virus disease 2019 outside Wuhan, China: A descriptive study. J Clin Virol 316 2020;129:104475. https://doi.org/10.1016/j.jcv.2020.104475. 317 [27] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult 318 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. 319 https://doi.org/10.1016/S0140-6736(20)30566-3. 320 [28] Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcomes of 221 patients 321 with COVID-19 in Wuhan, China. J Clin Virol 2020;127:104364. https://doi.org/10.1016/j.jcv.2020.104364. 322 [29] Shang Y, Liu T, Wei Y, Li J, Shao L, Liu M, et al. Scoring systems for predicting mortality for severe 323 patients with COVID-19. EClinicalMedicine 2020:100426. https://doi.org/10.1016/j.eclinm.2020.100426. 324 [30] Deng Q, Hu B, Zhang Y, Wang H, Zhou X, Hu W, et al. Suspected myocardial injury in patients with 325 COVID-19: Evidence from front-line clinical observation in Wuhan, China. Int J Cardiol 2020;311:116-21. 326 https://doi.org/10.1016/j.ijcard.2020.03.087. 327 [31] Cespedes M da S, Souza JCRP de. Sars-CoV-2: A clinical update - II. Rev Assoc Med Bras 2020;66:547-57. 328 https://doi.org/10.1590/1806-9282.66.4.547. 329 [32] Li J-W, Han T-W, Woodward M, Anderson CS, Zhou H, Chen Y-D, et al. The impact of 2019 novel 330 coronavirus on heart injury: A Systematic review and Meta-analysis. Prog Cardiovasc Dis 2020. 331 https://doi.org/10.1016/j.pcad.2020.04.008. 332 [33] Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with 333 mortality and critically ill pneumonia in COVID-19: A meta-analysis. Am J Emerg Med 2020. 334 https://doi.org/10.1016/j.ajem.2020.04.052. 335 [34] Shi S, Qin M, Yang B. Coronavirus Disease 2019 (COVID-19) and Cardiac Injury-Reply. JAMA Cardiol 336 2020. https://doi.org/10.1001/jamacardio.2020.2456. 337 [35] Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the 338 Cardiovascular System. JAMA Cardiol 2020;5:831. https://doi.org/10.1001/jamacardio.2020.1286. 339 [36] Martins-Filho PR, Barreto-Filho JAS, Santos VS. Biomarcadores de Lesão Miocárdica e Complicações

340		Cardíacas Associadas à Mortalidade em Pacientes com COVID-19. Arq Bras Cardiol 2020;115:273–7.
341		https://doi.org/10.36660/abc.20200372.
342	[37]	Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic
343		mechanisms to clinical perspectives. Nat Rev Cardiol 2020;17:543–58.
344		https://doi.org/10.1038/s41569-020-0413-9.
345	[38]	Gupta A, Madhavan M V., Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary
346		manifestations of COVID-19. Nat Med 2020;26:1017–32. https://doi.org/10.1038/s41591-020-0968-3.
347	[39]	Sardinha DM, Simor A, de Oliveira Moura LD, Silva AGI da, Batista Lima KV, Dias Garcez JC, et al. Risk
348		Factors for Acute Renal Failure after Cardiac Catheterization Most Cited in the Literature: An Integrative
349		Review. Int J Environ Res Public Health 2020;17. https://doi.org/10.3390/ijerph17103392.
350	[40]	Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in
351		patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.
352		https://doi.org/10.1111/jth.14768.
353	[41]	Biembengut ÍV, de Souza T de ACB. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for
354		COVID-19 treatment: an in silico approach. Mem Inst Oswaldo Cruz 2020;115.
355		https://doi.org/10.1590/0074-02760200179.
356	[42]	Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of
357		thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7.
358		https://doi.org/10.1016/j.thromres.2020.04.013.
359	[43]	Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial
360		thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.
361		Thromb Res 2020;191:9–14. https://doi.org/10.1016/j.thromres.2020.04.024.
362	[44]	Sardinha DM, Neiva Assis L de M e, Amoedo AS, Gonçalves KR de O, Melo RHD, Lima CAS, et al.
363		Nursing Diagnoses in Heart Failure: Integrative Review. Cardiol Angiol An Int J 2020:1-9.
364		https://doi.org/10.9734/ca/2020/v9i230129.
365	[45]	Bader F, Manla Y, Atallah B, Starling RC. Heart failure and COVID-19. Heart Fail Rev 2020.
366		https://doi.org/10.1007/s10741-020-10008-2.
367	[46]	Parohan M, Yaghoubi S, Seraji A. Cardiac injury is associated with severe outcome and death in patients
368		with Coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of
369		observational studies. Eur Hear J Acute Cardiovasc Care 2020:204887262093716.
370		https://doi.org/10.1177/2048872620937165.
371	[47]	Kochav SM, Coromilas E, Nalbandian A, Ranard LS, Gupta A, Chung MK, et al. Cardiac Arrhythmias in
372		COVID-19Infection.CircArrhythmElectrophysiol2020;13:e008719.
373		https://doi.org/10.1161/CIRCEP.120.008719.
374		